LDS/Medical Tests/CD4/CD8 Lymphocyte Ratio, Bronchoalvolar lavage

CD4/CD8 Lymphocyte Ratio, Bronchoalvolar lavage

T-cells are a type of white blood cell called lymphocytes and are a part of the cell-mediated immunity response. There are different T-cells that play a part in immunity and are distinguished by certain receptors or antigens present on their outer membrane. Also known as T-helper cells, CD4 T-cells have the CD-4 receptor on the surface membrane. The CD4 T-helper cells provide immunity by activating cytotoxic T cells, aiding B cell antibody class switching and enhancing the effectiveness of macrophages towards parasites and fungi.  Although CD4 cells can be a protector, they are the main target of the HIV virus which attaches itself to the CD4 receptor, enters the cell, and inactivates it. As the HIV virus replicates and increases, the CD4 cell count will decrease. Once the CD4 cell count decreases below 500 cells/uL (a normal healthy adult has >1000 cells/uL), patients will begin to receive anti-viral therapy.

CD8 cells, also known as cytotoxic T cells (aka "killer" T cells), will identify and kill cells that are infected with a virus or are abnormal such as cancer cells.  It is an important part of the immune surveillance system. When an infectious agent such as a virus enters a cell and begins to replicate and produce new viruses, they leave certain viral fragments behind. The CD8 cells specific for the antigens on these fragments will destroy the cell before it can create more virus. They do this by means of cytokine secretion such as gamma-interferon and by release of cytotoxic granules by way of cell surface granule components CD107a and CD107b, also known as lysosome associated membrane proteins 1 and 2 (LAMP-1 and LAMP-2).  When a patient is having treatment for HIV, it is desirable to have an increase in CD4 cells.  Healthy patients normally have a CD4:CD8 ratio of >1.0. This means one or more CD4 cell per CD8 cell. In people with HIV, the ratio decreases, meaning that there are many times more CD8 cells than CD4 cells. When the CD4 cell count decreases dramatically, symptoms of AIDS will appear in part because there are too few CD4 cells to activate the uninfected CD8 cells and so infectious agents like pneumocystis that would normally be controlled in part by CD8 killer cells are not presented to the CD8 cells for destruction. This makes the CD4 and CD8 count very important in starting or changing anti-viral therapy. CD8 will increase in other cancers and infections other than HIV such as measles, burns, or infectious mononucleosis. In addition to CD4 and CD8 enumeration, CD3, total white blood cell count and total lymphocyte counts are also reported.

  • In diagnosis of human immunodeficiency virus infection
  • Monitoring patients with human immunodeficiency virus infection
  • Therapy treatment decision making in patient with human immunodeficiency virus
  • As an aid in diagnosis of some other immunodeficiencies other then AIDS
  • Monitoring transplant and cancer patients

Increased CD4/CD8 Ratio in:

  • Inflammatory disease
  • Autoimmune diseases such as rheumatoid arthritis, SLE, and chronic autoimmune hepatitis
  • Type I diabetes mellitus
  • Primary biliary cirrhosis
  • Atopic dermatitis
  • Psoriasis

Decreased in:

  • AIDS/HIV infection
  • Acute cytomegalovirus (CMV) infection
  • Burns
  • Graft-versus-host disease
  • Myelodysplastic syndromes
  • Acute lymphoblastic leukemia in remission
  • Recovery from bone marrow transplantation
  • Infectious mononucleosis
  • Measles
  • Ataxia-telangiectasia
  • Some therapy treatment that might affect white blood cells proliferation

Total White Cell Count: 4,500-11,000/µL
Total Lymphocyte Count: 800-4,800/µL
CD4: 359 – 1725 cells/µL (29 – 61%)
CD8: 80 – 1400 cells/µL (8 - 41%)
CD3: 650 - 3100 cells/µL (65 - 90%)
CD4/CD8: >0.9

 

 

Flow cytometry

Bronchoalvolar lavage collected in a sterile container. 

Specimens must be kept at room temperature and analyzed within 72 hours of collection in EDTA or within 48 hours in heparin.

Some medications may affect immunophenotyping results and should be listed on the patient test request form.

Complete Blood Count (CBC) with Manual Diff, CD3, HIV Antibody Screen, HIV Western Blot, HIV Viral Load, HIV Genotypic Resistance Testing, HIV Phenotypic Resistance Testing, Lymphocyte Subset Panel.
2-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login